A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression
about
Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomesSecond-generation antipsychotics for major depressive disorder and dysthymiaChallenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved TherapeuticsSecond Generation Antipsychotics in the Treatment of Major Depressive Disorder: An UpdateEmerging targets for antidepressant therapiesCitalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical responseNovel targets for antidepressant therapiesPharmacologic approaches to treatment resistant depression: a re-examination for the modern era.UPLC-Tandem Mass Spectrometry Method for Simultaneous Determination of Fluoxetine, Risperidone, and Its Active Metabolite 9-Hydroxyrisperidone in Plasma: Application to Pharmacokinetics Study in Rats.Analysing psychosocial difficulties in depression: a content comparison between systematic literature review and patient perspectiveImprovement in self-reported quality of life with cognitive therapy for recurrent major depressive disorder.Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorderAugmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature.Antipsychotics as antidepressants.Lithium, but not fluoxetine or the corticotropin-releasing factor receptor 1 receptor antagonist R121919, increases cell proliferation in the adult dentate gyrus.Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.Antipsychotic Medications in Major Depression and the Association with Treatment Satisfaction and Quality of Life: Findings of Three National Surveys on Use of Psychotropics in China Between 2002 and 2012.Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis.The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder.Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder.Use of risperidone as augmentation treatment for major depressive disorder.Treatment strategies for dosing the second generation antipsychotics.Therapeutic options in treatment-resistant depression.Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders.Second-generation antipsychotics in the treatment of major depressive disorder: current evidence.The integrative management of treatment-resistant depression: a comprehensive review and perspectives.The preclinical discovery and development of brexpiprazole for the treatment of major depressive disorder.
P2860
Q21144599-87817220-B213-4FE0-9B09-270621CA9FEAQ24235667-20D270B3-0555-4A9C-B1BA-9E9CBC446CAEQ26782997-9C84842C-F770-4846-9ACE-BD12F6A19508Q28076712-94EAF7B0-9C8A-442E-B12C-C97F4A7E744CQ28247614-0DF88256-ECF5-4516-936F-1F03B763A4D7Q28306033-FCE67D7B-67EB-49A0-AE7B-B0495BB39005Q28648254-7DF5CEDB-AB82-42B4-94A7-CDA3BF670C1BQ33716723-159E1A2C-7F08-401E-9699-898427C44A4CQ33800810-EE948B5A-9714-4913-93DA-A887010B542EQ33804038-218AA27D-2EC4-4317-8562-73A9ABAB1E28Q33991058-B5028C01-6455-4415-842C-C2A1E085829BQ34010693-424C5470-F1BA-4B00-84BE-66C0A072175BQ34330761-BD7C4F38-DC6F-4454-B55D-F0E16A385172Q34475987-94823D04-7FD5-485C-8EF6-8E96A9C1926BQ34715718-6CD49712-F9BF-4446-8A05-C45AD566D289Q36091234-7414B695-57A2-42E3-8144-3EE4D41B50C4Q36477113-DAB417B7-86AD-4169-B0E9-83A4B3287549Q36588685-7E5FC2C2-D483-46FD-8BD9-5C2E29F4760CQ37141494-C490E269-8950-43B6-8B5E-2FC6D7E8742CQ37734565-73871934-2A6E-4EF2-BD16-C4E4203E1D0EQ37824372-63E77081-47BD-4747-8E23-6833C3075640Q37852818-B5F4BB98-9978-4A92-9240-FA3721E70070Q37881968-E91E2066-C879-4C4F-922F-48D7082BE19BQ38109589-FDCE565F-B775-4084-AD82-09EAF1722965Q38123516-EAD5EA9A-4D52-4CFB-B150-580DF370C57CQ38125219-667A0649-705C-492E-85B2-FCBD9E665534Q38181363-3E95712B-9435-49D7-ADA6-9247AB02BCDEQ38674314-5BE80B1B-993D-4626-885D-5909F897DE0F
P2860
A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
A randomized, placebo-controll ...... non-psychotic major depression
@en
type
label
A randomized, placebo-controll ...... non-psychotic major depression
@en
prefLabel
A randomized, placebo-controll ...... non-psychotic major depression
@en
P2093
P2860
P1476
A randomized, placebo-controll ...... non-psychotic major depression
@en
P2093
Charles B Nemeroff
Christine E Ryan
David A Solomon
Gabor I Keitner
Martin B Keller
Steven J Garlow
P2860
P304
P356
10.1016/J.JPSYCHIRES.2008.05.003
P50
P577
2008-06-30T00:00:00Z